OSU-2131

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameOSU-2131
Drug Alias NameOSU-2131
ClassificationVaccines > Development/production technology > Synthetic peptide vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsLymphoproliferative DisordersRenal Insufficiency, ChronicEpstein-Barr Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOhio State University Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOhio State University Comprehensive Cancer Center
Active IndicationsN/A
Inactive IndicationsLymphoproliferative DisordersRenal Insufficiency, ChronicEpstein-Barr Virus Infections

Other Information

ATC CodeN/A
Related LinksN/A